HRP20120165T1 - Novi pripravci na bazi taksoida - Google Patents
Novi pripravci na bazi taksoida Download PDFInfo
- Publication number
- HRP20120165T1 HRP20120165T1 HR20120165T HRP20120165T HRP20120165T1 HR P20120165 T1 HRP20120165 T1 HR P20120165T1 HR 20120165 T HR20120165 T HR 20120165T HR P20120165 T HRP20120165 T HR P20120165T HR P20120165 T1 HRP20120165 T1 HR P20120165T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparations according
- acid
- lecithin
- chosen
- preparations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 6
- 238000002360 preparation method Methods 0.000 claims abstract 18
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract 6
- 239000000787 lecithin Substances 0.000 claims abstract 6
- 229940067606 lecithin Drugs 0.000 claims abstract 6
- 235000010445 lecithin Nutrition 0.000 claims abstract 6
- 239000000839 emulsion Substances 0.000 claims abstract 5
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract 4
- 239000003945 anionic surfactant Substances 0.000 claims abstract 3
- 229940123237 Taxane Drugs 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims 5
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical group CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 3
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 2
- LHCZDUCPSRJDJT-UHFFFAOYSA-N dilauroyl phosphatidylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCC LHCZDUCPSRJDJT-UHFFFAOYSA-N 0.000 claims 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- 235000019198 oils Nutrition 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000008344 egg yolk phospholipid Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 235000012424 soybean oil Nutrition 0.000 claims 1
- 239000003549 soybean oil Substances 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Abstract
Pripravci koje se može injicirati u obliku emulzije koja sadrži derivate klase taksana, koji se sastoje od emulzije na bazi farmaceutski prihvatljivog ulja u vodi uz lecitin, što je pripravak u kojem se otapa taksan opće formule (I) ili (II), niže: naznačeni time što također sadrže anionski surfaktant. Patent sadrži još 15 patentnih zahtjeva.
Claims (16)
1. Pripravci koje se može injicirati u obliku emulzije koja sadrži derivate klase taksana, koji se sastoje od emulzije na bazi farmaceutski prihvatljivog ulja u vodi uz lecitin, što je pripravak u kojem se otapa taksan opće formule (I) ili (II), niže:
[image]
[image]
naznačeni time što također sadrže anionski surfaktant.
2. Pripravci u skladu s patentnim zahtjevom 1, naznačeni time što se farmaceutski prihvatljiva ulja bira između smjesa sojinog ulja i triglicerida srednje dugih lanaca.
3. Pripravci u skladu s patentnim zahtjevom 1, naznačeni time što je lecitin prirodni lecitin, kojeg se bira između lecitina iz jaja ili lecitina iz soje, ili polusintetski lecitin, kojeg se bira između fosfatidilkolina.
4. Pripravci u skladu s patentnim zahtjevom 1, naznačeni time što je anionski surfaktant fosfatidilglicerol ili fosfatidna kiselina.
5. Pripravci u skladu s patentnim zahtjevom 4, naznačeni time što se fosfatidilglicerol bira između dilauroilfosfatidilglicerola (DLPG), dimiristoilfosfatidilglicerola (DMPG) ili dipalmitoilfosfatidilglicerola (DPPG).
6. Pripravci u skladu s patentnim zahtjevom 4, naznačeni time što se fosfatidnu kiselinu bira između natrijevih soli dilauroilglicerofosfatidne kiseline (DLPA), dimiristoilglicerofosfatidne kiseline (DMPA) ili dipalmitoilglicerofosfatidne kiseline (DPPA).
7. Pripravci u skladu s patentnim zahtjevom 1, naznačeni time što je težinski omjer između fosfatidilkolina ili lecitina i fosfatidilglicerola ili fosfatidne kiseline po mogućnosti između 500 i 3.
8. Pripravci u skladu s patentnim zahtjevom 7, naznačeni time što težinski omjer je po mogućnosti između 100 i 10.
9. Pripravci u skladu s patentnim zahtjevom 1, naznačeni time što se pH formulacije podešava na između 3 i 7 dodavanjem kiseline.
10. Pripravci u skladu s patentnim zahtjevom 9, naznačeni time što se kiselinu bira između klorovodične, limunske ili askorbinske kiseline.
11. Pripravci u skladu s patentnim zahtjevom 1, naznačeni time što se dodaje pufer, koji je histidin.
12. Pripravci u skladu s patentnim zahtjevom 1, naznačeni time što se izotoničnost otopine podešava dodavanjem glicerola.
13. Pripravci u skladu s patentnim zahtjevom 1, naznačeni time što se težinski sastav formulacije kreće u sljedećim granicama:
[image]
14. Pripravci u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeni time što ih se primijenjuje intravenski, kao bolus.
15. Pripravci u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeni time što se veličina čestica kreće između 100 nm i 1 µm.
16. Postupak dobivanja pripravaka u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se emulziju dobiva uređajem za mikrofluidiziranje ili visokotlačnim homogenizatorom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0707092A FR2922107B1 (fr) | 2007-10-10 | 2007-10-10 | Nouvelles compositions a base de taxoides |
| PCT/FR2008/001410 WO2009083664A1 (fr) | 2007-10-10 | 2008-10-09 | Nouvelles compositions a base de taxoides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120165T1 true HRP20120165T1 (hr) | 2012-03-31 |
Family
ID=39356621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120165T HRP20120165T1 (hr) | 2007-10-10 | 2012-02-20 | Novi pripravci na bazi taksoida |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8481589B2 (hr) |
| EP (1) | EP2197492B1 (hr) |
| JP (1) | JP5574965B2 (hr) |
| KR (1) | KR20100075490A (hr) |
| CN (1) | CN101820918A (hr) |
| AR (1) | AR072333A1 (hr) |
| AT (1) | ATE534406T1 (hr) |
| AU (1) | AU2008345527A1 (hr) |
| BR (1) | BRPI0818597A2 (hr) |
| CA (1) | CA2701789A1 (hr) |
| CL (1) | CL2008003002A1 (hr) |
| CO (1) | CO6260107A2 (hr) |
| CR (1) | CR11335A (hr) |
| CY (1) | CY1112388T1 (hr) |
| DK (1) | DK2197492T3 (hr) |
| DO (1) | DOP2010000098A (hr) |
| EA (1) | EA016619B1 (hr) |
| ES (1) | ES2377352T3 (hr) |
| FR (1) | FR2922107B1 (hr) |
| GT (1) | GT201000075A (hr) |
| HR (1) | HRP20120165T1 (hr) |
| IL (1) | IL204950A0 (hr) |
| MA (1) | MA31840B1 (hr) |
| MX (1) | MX2010003914A (hr) |
| NI (1) | NI201000048A (hr) |
| NZ (1) | NZ584544A (hr) |
| PA (1) | PA8798101A1 (hr) |
| PE (1) | PE20090962A1 (hr) |
| PL (1) | PL2197492T3 (hr) |
| PT (1) | PT2197492E (hr) |
| RS (1) | RS52131B (hr) |
| SI (1) | SI2197492T1 (hr) |
| TN (1) | TN2010000129A1 (hr) |
| TW (1) | TW200922552A (hr) |
| UA (1) | UA97418C2 (hr) |
| UY (1) | UY31386A1 (hr) |
| WO (1) | WO2009083664A1 (hr) |
| ZA (1) | ZA201002504B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120065255A1 (en) * | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
| CA2779009A1 (en) | 2009-10-29 | 2011-05-05 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
| KR101752944B1 (ko) | 2010-05-03 | 2017-07-03 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법 |
| JP2012051823A (ja) * | 2010-08-31 | 2012-03-15 | Fujifilm Corp | 難容性薬物含有水中油型乳化組成物及びその製造方法 |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| CN104225615B (zh) * | 2014-09-24 | 2017-02-01 | 东南大学 | 一种紫杉醇类磷脂化合物、其药物组合物及应用 |
| EP3384961B1 (en) * | 2017-04-05 | 2021-10-13 | RaySearch Laboratories AB | System and method for modelling of dose calculation in radiotherapy treatment planning |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| FR2678833B1 (fr) | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| JP3208517B2 (ja) * | 1992-07-01 | 2001-09-17 | ブリストル−マイヤーズ スクイブ カンパニー | ７，８−シクロプロパタキサン類 |
| US5254580A (en) * | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| US5616330A (en) * | 1994-07-19 | 1997-04-01 | Hemagen/Pfc | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
| US6372780B2 (en) * | 1995-03-27 | 2002-04-16 | Aventis Pharma S.A. | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
| JP2002523364A (ja) * | 1998-08-20 | 2002-07-30 | アベンテイス・フアルマ・ソシエテ・アノニム | タキソイド誘導体の新規な使用 |
| US20020001613A1 (en) * | 2000-02-08 | 2002-01-03 | Susan Niemiec | Method of manufacturing liposomes |
| US20030099674A1 (en) | 2001-08-11 | 2003-05-29 | Chen Andrew X. | Lyophilized injectable formulations containing paclitaxel or other taxoid drugs |
| CN1794975A (zh) * | 2003-04-29 | 2006-06-28 | 巴克斯特国际公司 | 使抗微生物的药物有效抗通常认为抗该药物的生物体的制剂 |
| EP1498143A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| EP1498120A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
| US8557861B2 (en) * | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| JP5089887B2 (ja) * | 2006-01-23 | 2012-12-05 | 日本精化株式会社 | 生理活性物質含有複合体 |
-
2007
- 2007-10-10 FR FR0707092A patent/FR2922107B1/fr not_active Expired - Fee Related
-
2008
- 2008-09-24 TW TW097136649A patent/TW200922552A/zh unknown
- 2008-10-07 PE PE2008001737A patent/PE20090962A1/es not_active Application Discontinuation
- 2008-10-08 AR ARP080104386A patent/AR072333A1/es not_active Application Discontinuation
- 2008-10-08 PA PA20088798101A patent/PA8798101A1/es unknown
- 2008-10-09 PT PT08868434T patent/PT2197492E/pt unknown
- 2008-10-09 KR KR1020107007728A patent/KR20100075490A/ko not_active Application Discontinuation
- 2008-10-09 EA EA201070448A patent/EA016619B1/ru not_active IP Right Cessation
- 2008-10-09 CA CA2701789A patent/CA2701789A1/fr not_active Abandoned
- 2008-10-09 UA UAA201005592A patent/UA97418C2/ru unknown
- 2008-10-09 MX MX2010003914A patent/MX2010003914A/es active IP Right Grant
- 2008-10-09 BR BRPI0818597 patent/BRPI0818597A2/pt not_active IP Right Cessation
- 2008-10-09 AU AU2008345527A patent/AU2008345527A1/en not_active Abandoned
- 2008-10-09 AT AT08868434T patent/ATE534406T1/de active
- 2008-10-09 WO PCT/FR2008/001410 patent/WO2009083664A1/fr active Application Filing
- 2008-10-09 CN CN200880110996A patent/CN101820918A/zh active Pending
- 2008-10-09 NZ NZ584544A patent/NZ584544A/en not_active IP Right Cessation
- 2008-10-09 RS RS20120058A patent/RS52131B/en unknown
- 2008-10-09 JP JP2010528443A patent/JP5574965B2/ja active Active
- 2008-10-09 SI SI200830554T patent/SI2197492T1/sl unknown
- 2008-10-09 PL PL08868434T patent/PL2197492T3/pl unknown
- 2008-10-09 EP EP08868434A patent/EP2197492B1/fr active Active
- 2008-10-09 CL CL2008003002A patent/CL2008003002A1/es unknown
- 2008-10-09 ES ES08868434T patent/ES2377352T3/es active Active
- 2008-10-09 DK DK08868434.5T patent/DK2197492T3/da active
- 2008-10-10 UY UY31386A patent/UY31386A1/es unknown
-
2010
- 2010-03-22 TN TNP2010000129A patent/TN2010000129A1/fr unknown
- 2010-03-24 CR CR11335A patent/CR11335A/es not_active Application Discontinuation
- 2010-04-06 GT GT201000075A patent/GT201000075A/es unknown
- 2010-04-08 IL IL204950A patent/IL204950A0/en unknown
- 2010-04-08 NI NI201000048A patent/NI201000048A/es unknown
- 2010-04-08 DO DO2010000098A patent/DOP2010000098A/es unknown
- 2010-04-09 CO CO10041381A patent/CO6260107A2/es not_active Application Discontinuation
- 2010-04-09 US US12/757,255 patent/US8481589B2/en active Active
- 2010-04-09 ZA ZA2010/02504A patent/ZA201002504B/en unknown
- 2010-05-10 MA MA32825A patent/MA31840B1/fr unknown
-
2012
- 2012-02-20 HR HR20120165T patent/HRP20120165T1/hr unknown
- 2012-02-23 CY CY20121100186T patent/CY1112388T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120165T1 (hr) | Novi pripravci na bazi taksoida | |
| RU2007144071A (ru) | Стабильная эмульсионная композиция | |
| KR101507097B1 (ko) | 4급 암모늄 화합물 함유 조성물 | |
| US11103455B2 (en) | Liposomal compositions and methods of use | |
| KR101365252B1 (ko) | 포스파티딜콜린 함유 주사용 조성물 및 이의 제조방법 | |
| WO2018035030A1 (en) | Time release fat-soluble actives | |
| EA201100069A1 (ru) | Стабильная инъецируемая наноэмульсия доцетакселя | |
| RS53127B (en) | STABLE PROTEIN FORMULATIONS | |
| US20110053903A1 (en) | Pharmaceutical compositions based on azetidine derivatives | |
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| KR101355216B1 (ko) | 경피 흡수 촉진용 리포좀을 포함하는 조성물이 적용된 마스크 시트 | |
| JP2013536805A (ja) | 難溶性薬物の液体組成物及びその調製方法 | |
| JP2015030705A (ja) | セラミド分散組成物 | |
| JP2009256377A (ja) | 乳化組成物の調製方法 | |
| HRP20120484T1 (hr) | Postupak i kompozicija za liječenje rinitisa | |
| NZ591205A (en) | Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same | |
| US10849844B2 (en) | Formulations for treatment of skin and methods of making and using the same | |
| BR112019014705A2 (pt) | Tratamento que compreende a administração oral ou gástrica de edaravone | |
| JP2014156456A (ja) | 皮膚外用剤 | |
| JP6005863B2 (ja) | 液体洗浄剤組成物 | |
| MXPA04005558A (es) | Composiciones farmaceuticas a base de derivados de azetidina. | |
| CN102008729A (zh) | 外用组合物 | |
| EP3265177B1 (en) | Formulations of hydrophilic compounds | |
| JP2006213699A (ja) | 皮膚外用剤 | |
| MX2020010290A (es) | Composiciones anestesicas de liberacion sostenida y metodos de preparacion de las mismas. |